Why the study?
Does the use of polymer-free biolimus-eluting stents provide a favorable safety and efficacy profile in all-comer patients irrespective of high bleeding risk status?
Does the use of polymer-free biolimus-eluting stents provide a favorable safety and efficacy profile in all-comer patients irrespective of high bleeding risk status?
Polymer-free biolimus-eluting stents demonstrate a favorable safety and efficacy profile in a real-world all-comer population, supporting the need for future randomized trials against new-generation DES.
Answers are grounded in this paper and cite their sources.
Supports PF-BES consideration in real-world all-comers; leaves open direct RCTs versus new-generation DES.
This is the first study providing clinical evidence on the use of PF-BES in all-comer patients irrespective of HBR status. Our findings suggest that PF-BES has a favourable safety and efficacy profile in a real-world clinical setting. Further investigation in randomised clinical trials against new-generation DES is warranted.
No takes yet. Share an insight, caveat, or question.
Sardella et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: